Recent Updates
Recently added Catalysts
FBIO Positive Sentiment

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Key Takeaway: Fortress Biotech, Inc. will participate in A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. CEO Lindsay A. Rosenwald will engage in a fireside chat during the event. Fortress focuses on acquiring and advancing biopharmaceutical assets to enhance shareholder value through various revenue streams.
Price reaction · baseline $2.41 (2026-05-15 close) · clean, no other FBIO news in the window
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Fortress Biotech is actively participating in a prominent healthcare conference.
  • The company has a diverse portfolio of marketed products and ongoing programs.
  • Fortress has established partnerships with leading academic and biopharmaceutical institutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+115%
120-day peak, hindsight
Typical move
12.1%
average across 5 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
CK-301
Phase 1 · Lung Neoplasms

Full Press Release Details

MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 12:20pm ET.
To register for the conference, visit theA.G.P. Registration Link.
About Fortress BiotechFortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visitwww.fortressbiotech.com.

Company Contact:Jaclyn JaffeFortress Biotech, Inc.(781) 652-4500ir@fortressbiotech.com

Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

Frequently Asked Questions

When is Fortress Biotech participating in the A.G.P. Conference?

Fortress Biotech will participate in the A.G.P. Annual Virtual Healthcare Conference on May 20, 2026.

Who will represent Fortress Biotech at the conference?

Lindsay A. Rosenwald, M.D., the CEO of Fortress Biotech, will represent the company.

What is the focus of Fortress Biotech?

Fortress Biotech focuses on acquiring and advancing biopharmaceutical assets to enhance shareholder value.

What types of products does Fortress Biotech develop?

Fortress Biotech develops products in various therapeutic areas, including oncology and rare diseases.

Last updated: May 18, 2026